- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06495450
Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke (PROVE)
PROVE-VR: A Pilot Randomized Trial Using Omnidirectional Virtual Reality and Treadmill Training for Chronic Stroke Survivors
The primary objective of this pilot randomized controlled trial (RCT) is to test the feasibility (consent rate, retention rate, participant burden, adherence, technical issues, safety) and usability (system usability scale, SUS) of Omnidirectional treadmill Virtual Reality training (omni-VR) among chronic stroke survivors. Our secondary objective is to (1) estimate the extent to which cognition, brain activation during a dual task activity, walking ability, and dynamic balance change after 3 months of training among intervention participants (omni-VR) and traditional exercise controls, and (2) estimate the extent to which health-related quality of life and motivation co-evolve with our secondary outcomes.
Researchers will compare the intervention group and control group to evaluate the impact of omni-VR on cognition and physical function among stroke survivors.
Participants will:
- undergo a 45-minute training session 3 times per week for 12 weeks
- intervention group: omni-VR
- control group: traditional exercise program (strengthening and walking activities)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Mounting data indicates that cognition plays a role in complex walking and balance. However, conventional intervention methods lack a sufficient incentive to encourage participants to adhere to the treatment. Further, it is difficult to provide a substantial amount of treatment to induce cortical reorganization.
Virtual reality or VR (a computer-generated simulation of 3-dimensional virtual environments that reacts in real time to the user's actions) has been introduced to neurorehabilitation to promote improvements in walking ability, balance, and cognition. It has also been demonstrated to be effective in improving motivation among stroke survivors and augmenting neuroplasticity.
Omnidirectional treadmill technology can be integrated with VR to allow for fully immersive rehabilitation. This novel and innovative technology mimics real-world environments and maximizes challenging cognitive and physical dual-tasking and balance activities while maintaining patient safety. However, no randomized trials have evaluated the impact of omnidirectional treadmill VR (Omni-VR) on cognitive and physical function among stroke survivors.
Therefore, our study aims to test the feasibility and usability of the Omni-VR. This pilot randomized control trial will also be the first study to test the feasibility and effect of a fully-immersive active omni-VR system among chronic stroke survivors
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Adria Quigley, PhD
- Phone Number: 902-494-2734
- Email: adriaquigley@dal.ca
Study Locations
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 4K4
- Recruiting
- Nova Scotia Rehabilitation & Arthritis Centre
-
Contact:
- Adria Quigley, PhD
- Phone Number: 902-494-2734
- Email: adriaquigley@dal.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria
- Age ≥ 18
- Stroke ≥ 6 months ago (confirmed with chart review)
- Living within 50 km of Halifax, Nova Scotia
- Functional Ambulation Category of 3 or greater on a scale of 0-5, to ensure the participant is able to walk with supervision or independently. This criterion was selected to ensure participants could safely participate in the intervention.
- Ability to participate in low-moderate intensity aerobic or strengthening exercise for ≥ 15 minutes to ensure participants can tolerate intervention sessions of 30-45 minutes, with activity breaks, in keeping with previous stroke rehabilitation studies.
- No uncorrected visual deficits or spatial neglect
- No cardiovascular, orthopedic, or neurological diseases other than stroke impacting walking or balance
- Can follow simple instructions
- Score of < 27 on the adapted Motion Sickness Susceptibility Scale-Short based on established normative values indicating more than moderate susceptibility to motion sickness.
Exclusion Criteria:
- Unstable serious medical condition
- Resting blood pressure >180/100mmHg
- History of abnormal untreated heart rhythm
- Pregnancy
- Condition limiting ability to complete or tolerate the exercises without major program modifications (e.g., chronic low back pain)
- Serious comorbid condition that would affect participation in the intervention (e.g., active cancer, severe heart disease)
- Severe loss of hearing or speech that would preclude VR use
- Participant weight more than 264 lbs (weight limit for Virtualizer Elite 2 treadmill)
- Participating in another formal lower limb exercise program > 1 day per week
- History of QT prolongation or using potential QT prolonging drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Omni-VR group
20 participants will undergo 45-minute training sessions 3 times per week for 12 weeks using omnidirectional virtual reality and treadmill training.
|
Omni-VR forest scenario developed by our team involving real-life dual task walking and dynamic balance activities (ie.
stepping over obstacles, and managing distractions) will be used for treatment group.
|
|
Active Comparator: Control group
10 participants will undergo 45-minute traditional physiotherapy training sessions including lower limb strengthening and unidirectional treadmill training 3 times per week for 12 weeks.
|
A traditional exercise program including strengthening and unidirectional treadmill activities for the same duration will be completed in control group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retention rate
Time Frame: 12 weeks (study completion)
|
Retention rate is the percentage of participants who complete the 12-week intervention.
The investigators expect a retention rate of 80% for the intervention group.
|
12 weeks (study completion)
|
|
Usability of the Omnidirectional Treadmill and Virtual Reality Game
Time Frame: 12 weeks (study completion)
|
Usability will be assessed by System Usability Scale (SUS) out of 100 points.
The investigators expect a SUS score of 71 or higher among all participants.
|
12 weeks (study completion)
|
|
Participant burden
Time Frame: Baseline and 12 weeks (study completion)
|
Participant burden will be measured by the percentage of participants finishing assessments in 100 minutes or less.
The investigators anticipate at least 85% of participants completing assessments within the time limit.
|
Baseline and 12 weeks (study completion)
|
|
Adherence
Time Frame: 12 weeks (study completion)
|
Adherence will be measured by the exercise session attendance.
The investigators expect the treatment group to attend 70% or more of the sessions.
|
12 weeks (study completion)
|
|
Consent rate
Time Frame: Baseline
|
Consent rate is the percentage of eligible individuals who participate.
The investigators expect a consent rate of at least 40%.
|
Baseline
|
|
Equipment downtime
Time Frame: 12 weeks (study completion)
|
The investigators will record any treadmill downtime due to VR technical issues.
The targets are zero significant downtime in 85% of sessions.
|
12 weeks (study completion)
|
|
Equipment safety
Time Frame: 12 weeks (study completion)
|
The investigators will record any serious adverse events related to the study.
The target is no serious adverse events related to the study
|
12 weeks (study completion)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dynamic balance
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will measure the static sway with feet together using omni-VR system and use MINI-BESTest to measure the dynamic balance.
|
Baseline and 12 weeks (study completion)
|
|
Cognitive function
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will use the Computerized MoCA [Montreal Cognitive Assessment] Duo to evaluate participants' cognitive function.
|
Baseline and 12 weeks (study completion)
|
|
Executive Function
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will use the Dimensional Change Card Sort to evaluate participants' executive function.
|
Baseline and 12 weeks (study completion)
|
|
Working memory
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will use the List Sorting Working Memory Test to evaluate participants' working memory.
|
Baseline and 12 weeks (study completion)
|
|
Brain activation in prefrontal and premotor cortices
Time Frame: Baseline and 12 weeks (study completion)
|
Brain activation using fNIRS [Functional near-infrared spectroscopy] in the prefrontal and premotor regions of interest during a single task (steady-state omnidirectional treadmill walking) and two cognitive-physical dual-task activities (simple dual-task: steady-state omnidirectional treadmill walking while repeating the same word and complex dual-task: steady-state omnidirectional treadmill walking while performing a verbal fluency test)
|
Baseline and 12 weeks (study completion)
|
|
Walking Speed
Time Frame: Baseline and 12 weeks (study completion)
|
Walking speed using VIVE trackers on omnidirectional treadmill and overground
|
Baseline and 12 weeks (study completion)
|
|
Step cadence
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will evaluate step cadence using the VIVE trackers.
|
Baseline and 12 weeks (study completion)
|
|
Step width
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will evaluate step width using the VIVE trackers.
|
Baseline and 12 weeks (study completion)
|
|
Step length
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will evaluate step length using the VIVE trackers.
|
Baseline and 12 weeks (study completion)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Motivation of participant
Time Frame: 12 weeks (study completion)
|
The investigators will measure motivation by intrinsic motivation inventory.
Higher scores indicate better results.
|
12 weeks (study completion)
|
|
Health-related quality of life of participant
Time Frame: Baseline and 12 weeks (study completion)
|
The investigators will measure health-related quality of life by the Stroke Impact Scale-3.0.
Higher scores indicate better results.
|
Baseline and 12 weeks (study completion)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PROVE_stroke
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
National Assembly ClinicBayero University Kano, NigeriaRecruitingStroke | Stroke Hemorrhagic | Stroke Ischemic | Hemiparesis After StrokeNigeria
-
University of PittsburghRecruitingHemorrhagic Stroke | Embolic Stroke of Undetermined Source | Ischemic Stroke, Cryptogenic | Recurrent Ischemic Stroke | Ischemic Stroke, EmbolicUnited States
-
Mahidol UniversityNot yet recruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke SurvivorsThailand
-
Mahidol UniversityRecruitingIschemic Stroke | Hemorrhagic Stroke | Subacute Stroke | Chronic Stroke PatientThailand
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
University of Illinois at ChicagoRecruitingStroke, Ischemic | Stroke Hemorrhagic | Stroke, CerebrovascularUnited States
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Samsung Medical CenterCompletedChronic Stroke | Subacute Stroke | ExoskeletonSouth Korea
-
Fondazione Don Carlo Gnocchi OnlusScuola Superiore Sant'Anna di Pisa; Fondazione Policlinico Universitario Campus...Not yet recruitingStroke | Stroke Hemorrhagic | Upper Limb Rehabilitation | Stroke IschemicItaly
Clinical Trials on Omnidirectional Virtual Reality and Treadmill Training
-
University of Kansas Medical CenterNot yet recruitingMotoric Cognitive Risk SyndromeUnited States
-
Universitat de LleidaUniversity of Maryland, Baltimore; University of TurkuRecruiting
-
University of Vic - Central University of CataloniaNot yet recruitingCerebral Palsy, SpasticSpain
-
Fondazione Don Carlo Gnocchi OnlusUnknownStroke | Multiple Sclerosis | Parkinson DiseaseItaly
-
Somogy Megyei Kaposi Mór Teaching HospitalRecruiting
-
Tel-Aviv Sourasky Medical CenterCompletedMultiple SclerosisIsrael, United States
-
VA Office of Research and DevelopmentCompletedTranstibial AmputationUnited States
-
Seoul National University HospitalMinistry of Trade, Industry & Energy(MOTIE, Korea)CompletedVirtual Reality; Rehabilitation; Parkinson's DiseaseKorea, Republic of
-
Kessler FoundationRecruitingTraumatic Brain InjuryUnited States
-
Tel-Aviv Sourasky Medical CenterKU Leuven; Newcastle University; Universita degli Studi di Genova; University Medical...CompletedParkinson | Mild Cognitive Disorder | Elderly AdultsIsrael, Belgium, Italy, Netherlands, United Kingdom